Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A third of patients treated with Opdivo plus Yervoy experienced complete or partial tumor remission.
The International Liver Conference will be held in August 2020.
We all know the rules for living post-op, but this new strain has me feeling even more restricted.
A triple regimen of Opdivo, Yervoy and Cabometyx showed good activity, but side effects may limit its use.
Transplants due to hepatitis C have declined dramatically thanks to effective treatment.
Those with fatty liver disease and cirrhosis should undergo regular screening.
TRK inhibitor larotrectinib led to durable responses in people with colon, pancreatic, appendix, bile duct and liver cancers.
Tecentriq plus Avastin improved improved overall survival and patient experiences during treatment.
Americans are drinking more, which puts them at risk of alcohol-related liver disease, heart disease, cancer and accidents.
The LIVER Act would increase funding for liver cancer and hepatitis B research and prevention.
Cancer mortality fell by 29% between 1991 and 2017, largely driven by a decline in lung cancer deaths.
Three fatty liver disease candidates miss the mark for effectiveness or safety.
The 2019 Liver Meeting in Boston provided an array of important findings about the treatment and prevention of chronic liver diseases.
So found a study of more than 1,500 people treated for hep C, including almost 600 people with compensated advanced chronic liver disease.
Curing hep C slashes risk of death for those with liver cancer history
Currently, there are no pharmacological treatments for liver fibrosis related to non-alcoholic steatohepatitis.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.